| 2026-08-06 | 10-Q | 10.1 | Asset Purchase Agreement, dated June 12, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.2 | Revenue Participation Right Purchase and Sale Agreement by and between Denali Therapeutics Inc. and Royalty Pharma Investments 2023 ICAV Dated as of December 2, 2025 |
|---|
| 2026-05-07 | 10-Q | 10.1 | Amended and Restated Outside Director Compensation Policy |
|---|
| 2025-06-03 | 8-K | 10.1 | Affiliate Registration Rights Agreement, dated June 3, 2025, by and among the Company, Baker Brothers Life Sciences, L.P. and 667, L.P. |
|---|
| 2025-05-06 | 10-Q | 10.3 | Amended Outside Director Compensation Policy |
|---|
| 2025-05-06 | 10-Q | 10.2 | Notice of Partial Termination from Takeda Pharmaceutical Company Limited to the Registrant, dated February 25, 2025 |
|---|
| 2025-05-06 | 10-Q | 10.1 | Notice of Partial Termination from Genzyme Corporation to the Registrant, dated February 24, 2025 |
|---|
| 2024-08-01 | 10-Q | 10.1 | Denali - Biogen Side Letter. |
|---|
| 2024-02-28 | 10-K | 10.35 | Denali Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities as amended through March 31, 2023 |
|---|
| 2024-02-28 | 10-K | 10.34 | Compensation Recovery Policy (“Clawback Policy”) |
|---|
| 2024-02-27 | 8-K | 10.2 | Nominating Agreement by and among the Company and Investor |
|---|
| 2024-02-27 | 8-K | 10.1 | Securities Purchase Agreement, dated February 27, 2024, by and among the Company and the Purchasers named therein. |
|---|
| 2023-11-07 | 10-Q | 10.1 | Amendment to Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement. |
|---|
| 2023-02-27 | 10-K | 10.129 | Amendment No. 9 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated December 7, 2022. |
|---|
| 2023-02-27 | 10-K | 10.128 | Amendment No. 8 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 8, 2022. |
|---|
| 2023-02-27 | 10-K | 10.127 | Amendment No. 7 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated March 29, 2021. |
|---|
| 2022-02-28 | 10-K | 10.15 | Amended and Restated Outside Director Compensation Policy. |
|---|
| 2021-08-04 | 10-Q | 10.1 | Side Letter between the Registrant and F-star Gamma Limited, dated June 30, 2021 |
|---|
| 2021-05-05 | 10-Q | 10.1 | Amended and Restated Outside Director Compensation Policy |
|---|
| 2021-02-26 | 10-K | 10.15 | Amended and Restated Outside Director Compensation Policy. |
|---|
| 2021-02-26 | 10-K | 10.12.6 | Amendment No. 6 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017, Amendment No. 2 dated January 18, 2018, Amendment No. 3 dated July 2, 2018, Amendment No. 4 dated August 30, 2018, Amendment No. 5 dated August 6, 2019 and Amendment No. 3 dated September 11, 2020, dated December 8, 2020. |
|---|
| 2021-02-26 | 10-K | 10.12.5 | Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017, Amendment No. 2 dated January 18, 2018, Amendment No. 3 dated July 2, 2018, Amendment No. 4 dated August 30, 2018 and Amendment No. 5 dated August 6, 2019, dated September 11, 2020. |
|---|
| 2021-02-26 | 10-K | 10.12.4 | Amendment No. 5 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017, Amendment No. 2 dated January 18, 2018, Amendment No. 3 dated July 2, 2018 and Amendment No. 4 dated August 30, 2018, dated August 6, 2019. |
|---|
| 2020-11-05 | 10-Q | 10.6 | Form of Amended and Restated Change in Control and Severance Plan. |
|---|
| 2020-11-05 | 10-Q | 10.5 | Definitive Right of First Negotiation, Option and License Agreement between the Registrant and Biogen Inc., dated October 6, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.4 | Definitive LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated October 4, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.3 | Standstill and Stock Restriction Agreement between the Registrant and Biogen Inc., dated September 22, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.2 | Provisional LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated August 5, 2020. |
|---|
| 2020-11-05 | 10-Q | 10.1 | Common Stock Purchase Agreement between the Registrant and Biogen Inc., dated August 5, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.1 | Amended and Restated Outside Director Compensation Policy |
|---|
| 2019-03-12 | 10-K | 10.25 | Collaboration and License Agreement between registrant and Genzyme Corporate ("Sanofi"), dated October 29, 2018 |
|---|
| 2018-12-06 | 10-Q/A | 10.4 | Share Purchase Agreement between the Registrant, certain shareholders of F-star Gamma Limited and Shareholder Representative Services LLC, dated May 30, 2018. |
|---|
| 2018-12-06 | 10-Q/A | 10.2 | Amended and Restated Licence Agreement between F-star Gamma Limited and F-star Biotechnology Limited, dated August 24, 2016. |
|---|
| 2018-11-08 | 10-Q | 10.2 | Amendment No. 4 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017, Amendment No. 2 on January 18, 2018 and Amendment No. 3 on July 2. 2018, dated August 30, 2018. |
|---|
| 2018-11-08 | 10-Q | 10.1 | Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017 and Amendment No. 2 on January 18, 2018, dated July 2. 2018. |
|---|
| 2018-08-09 | 10-Q | 10.4 | Share Purchase Agreement between the Registrant, certain shareholders of F-star Gamma Limited and Shareholder Representative Services LLC, dated May 30, 2018. |
|---|
| 2018-08-09 | 10-Q | 10.3 | Side Letter between the Registrant, F-Star Gamma Limited, F-Star Biotechnology Limited and f-star Biotechnologische Forschungs-und Entwicklungsges m.b.H., dated May 21, 2018. |
|---|
| 2018-08-09 | 10-Q | 10.2 | Amended and Restated Licence Agreement between F-star Gamma Limited and F-star Biotechnology Limited, dated August 24, 2016. |
|---|
| 2018-08-09 | 10-Q | 10.1 | First Amendment to Lease between the Registrant and HCP Oyster Point III LLC, dated May 2, 2018. |
|---|
| 2018-07-13 | 10-K/A | 10.16 | Option and Collaboration Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018. |
|---|
| 2018-03-19 | 10-K | 10.18 | Standstill and Stock Restriction Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated February 23, 2018. |
|---|
| 2018-03-19 | 10-K | 10.17 | Common Stock Purchase Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018. |
|---|
| 2018-03-19 | 10-K | 10.16 | Option and Collaboration Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018. |
|---|
| 2018-03-19 | 10-K | 10.12.1 | Amendment No. 2 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October 18, 2017, dated January 18, 2018. |
|---|